CAMBRIDGE, Mass.—-Gloucester Pharmaceuticals, Inc., an oncology focused biopharmaceutical company, announced today that two abstracts detailing results from clinical trials of the Company’s lead product candidate, romidepsin, will be presented at the 2007 American Society of Hematology’s 49th Annual Meeting, to be held December 8-11 in Atlanta, Georgia.
No related posts.